Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07069270
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
A Prospective, Single-center, Single-arm Clinical Study of Adebrelimab in Combination With Vunakizumab and Chemotherapy as First-line Treatment for Extensious-stage Small Cell Lung Cancer
Sponsor: Fujian Cancer Hospital
Conditions
Adebrelimab Small Cell Lung Cancer Vunakizumab
Interventions
Adebrelimab Chemotherapy Vunakizumab (IL-17A inhibitor)
Updated 1 time since 2025 Last updated: Jul 7, 2025 Started: Sep 1, 2025 Primary completion: Jun 1, 2026 Completion: Jan 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Adebrelimab and Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Fujian Cancer Hospital and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fujian Cancer Hospital
Data source: Fujian Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.